Journal article
Mania and mortality: why the excess cardiovascular risk in bipolar disorder?
Current psychiatry reports, Vol.11(6), pp.475-480
12/2009
DOI: 10.1007/s11920-009-0072-3
PMID: 19909670
Abstract
Individuals with bipolar disorder experience twice the cardiovascular mortality expected from general population estimates. The metabolic syndrome is more common in those with bipolar disorder, with a prevalence ratio of 1.6, and includes many traditional cardiovascular risk factors, which may explain much of the elevated risk. Manic symptom burden also predicts cardiovascular mortality, begging questions regarding other explanations for elevated cardiovascular risk. Ultimately, the mechanisms that lead to elevated cardiovascular risk in bipolar disorder are complex and potentially involve behavior, treatment, access to quality health care, and underlying pathophysiology. Much remains unknown about the etiology of any mechanisms inherent to illness or, for that matter, treatment effects. Addressing access and health behaviors can mitigate risk for individuals with bipolar disorder. Recent evidence indicates that psychiatrists are becoming aware of the vascular risk associated with bipolar disorder, although further education will improve monitoring and subsequent outcomes.
Details
- Title: Subtitle
- Mania and mortality: why the excess cardiovascular risk in bipolar disorder?
- Creators
- Dylan P Murray - Department of Psychiatry, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242-1000, USAMiriam WeinerMaithri PrabhakarJess G Fiedorowicz
- Resource Type
- Journal article
- Publication Details
- Current psychiatry reports, Vol.11(6), pp.475-480
- Publisher
- United States
- DOI
- 10.1007/s11920-009-0072-3
- PMID
- 19909670
- ISSN
- 1535-1645
- eISSN
- 1535-1645
- Grant note
- Acknowledgment Dr. Fiedorowicz is supported by grant L30 MH075180-02, the Nellie Ball Research Trust Fund, and a NARSAD Young Investigator Award. Disclosure Dr. Fiedorowicz has received support for participating in a colleague’s investigator-initiated project from Eli Lilly and Company and currently collaborates on colleagues’ studies with Neurosearch and Vitalin/Enzymatic Therapy. No other potential confl icts of interest relevant to this article were reported.
- Language
- English
- Date published
- 12/2009
- Academic Unit
- Psychiatry; Epidemiology; Internal Medicine
- Record Identifier
- 9983931743702771
Metrics
19 Record Views